FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2794351393> ?p ?o ?g. }

• W2794351393 endingPage "108" @default.
• W2794351393 startingPage "101" @default.
• W2794351393 abstract "The role of antiangiogenic agents in advanced renal cell carcinoma (RCC) is well established. However, it is still not clear whether this benefit can be extrapolated to the adjuvant setting.To determine the efficacy and safety of antiangiogenic agents in patients with RCC and a high risk of relapse after nephrectomy.We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials for randomized controlled trials (RCTs) evaluating the use of any oral antiangiogenic agent compared to placebo in post-nephrectomy RCC patients. Prespecified data elements were extracted from each trial. Outcomes of interest included overall survival (OS) and disease-free survival (DFS). The overall effect was pooled using the DerSimonian and Laird random-effects models.Three RCTs comparing antiangiogenics to placebo among 3693 patients met our inclusion criteria and were used in meta-analyses. Overall, antiangiogenics did not improve DFS (hazard ratio [HR] 0.92, 95% confidence interval [CI] 0.78-1.07) or OS (HR 0.99, 95% CI 0.79-1.25). These results persisted when restricting the analysis to patients with clear cell carcinoma and patients with highest risk of relapse. Similarly, sunitinib did not show any improvement in the entire cohort for either DFS (HR 0.89, 95% CI 0.67-1.19) or OS (HR 1.11, 95% CI 0.90-1.37).In this meta-analysis, antiangiogenics did not improve OS and DFS over placebo in high-risk RCC after nephrectomy. Further studies are needed to identify the patient population that might derive a benefit from antiangiogenics in the adjuvant setting.In this article, we found that there is currently insufficient evidence to support the use of oral antiangiogenics in nonmetastatic renal cell carcinoma after nephrectomy. In addition, the use of oral antiangiogenics was associated with a 2.7-fold higher rate of significant side effects compared to placebo." @default.
• W2794351393 created "2018-03-29" @default.
• W2794351393 creator A5034715033 @default.
• W2794351393 creator A5035100026 @default.
• W2794351393 creator A5058650905 @default.
• W2794351393 creator A5059366804 @default.
• W2794351393 creator A5065058975 @default.
• W2794351393 creator A5065062293 @default.
• W2794351393 creator A5070784780 @default.
• W2794351393 date "2018-06-01" @default.
• W2794351393 modified "2023-09-27" @default.
• W2794351393 title "Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis" @default.
• W2794351393 cites W2098923148 @default.
• W2794351393 cites W2099326967 @default.
• W2794351393 cites W2134833483 @default.
• W2794351393 cites W2148741545 @default.
• W2794351393 cites W2168403132 @default.
• W2794351393 cites W2293077587 @default.
• W2794351393 cites W2530419161 @default.
• W2794351393 cites W2566129761 @default.
• W2794351393 cites W2570618306 @default.
• W2794351393 cites W2588681363 @default.
• W2794351393 cites W2594458845 @default.
• W2794351393 cites W2601917824 @default.
• W2794351393 cites W2741958254 @default.
• W2794351393 cites W2756219586 @default.
• W2794351393 cites W2758082149 @default.
• W2794351393 cites W2763081391 @default.
• W2794351393 cites W2766259009 @default.
• W2794351393 doi "https://doi.org/10.1016/j.euo.2018.03.012" @default.
• W2794351393 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6192050" @default.
• W2794351393 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30345423" @default.
• W2794351393 hasPublicationYear "2018" @default.
• W2794351393 type Work @default.
• W2794351393 sameAs 2794351393 @default.
• W2794351393 citedByCount "8" @default.
• W2794351393 countsByYear W27943513932019 @default.
• W2794351393 countsByYear W27943513932020 @default.
• W2794351393 countsByYear W27943513932021 @default.
• W2794351393 countsByYear W27943513932022 @default.
• W2794351393 countsByYear W27943513932023 @default.
• W2794351393 crossrefType "journal-article" @default.
• W2794351393 hasAuthorship W2794351393A5034715033 @default.
• W2794351393 hasAuthorship W2794351393A5035100026 @default.
• W2794351393 hasAuthorship W2794351393A5058650905 @default.
• W2794351393 hasAuthorship W2794351393A5059366804 @default.
• W2794351393 hasAuthorship W2794351393A5065058975 @default.
• W2794351393 hasAuthorship W2794351393A5065062293 @default.
• W2794351393 hasAuthorship W2794351393A5070784780 @default.
• W2794351393 hasBestOaLocation W27943513931 @default.
• W2794351393 hasConcept C126322002 @default.
• W2794351393 hasConcept C141071460 @default.
• W2794351393 hasConcept C142724271 @default.
• W2794351393 hasConcept C143998085 @default.
• W2794351393 hasConcept C168563851 @default.
• W2794351393 hasConcept C204787440 @default.
• W2794351393 hasConcept C207103383 @default.
• W2794351393 hasConcept C27081682 @default.
• W2794351393 hasConcept C2777472916 @default.
• W2794351393 hasConcept C2779490328 @default.
• W2794351393 hasConcept C2780091579 @default.
• W2794351393 hasConcept C2780227381 @default.
• W2794351393 hasConcept C2781068499 @default.
• W2794351393 hasConcept C2908647359 @default.
• W2794351393 hasConcept C44249647 @default.
• W2794351393 hasConcept C71924100 @default.
• W2794351393 hasConcept C82789193 @default.
• W2794351393 hasConcept C95190672 @default.
• W2794351393 hasConcept C99454951 @default.
• W2794351393 hasConceptScore W2794351393C126322002 @default.
• W2794351393 hasConceptScore W2794351393C141071460 @default.
• W2794351393 hasConceptScore W2794351393C142724271 @default.
• W2794351393 hasConceptScore W2794351393C143998085 @default.
• W2794351393 hasConceptScore W2794351393C168563851 @default.
• W2794351393 hasConceptScore W2794351393C204787440 @default.
• W2794351393 hasConceptScore W2794351393C207103383 @default.
• W2794351393 hasConceptScore W2794351393C27081682 @default.
• W2794351393 hasConceptScore W2794351393C2777472916 @default.
• W2794351393 hasConceptScore W2794351393C2779490328 @default.
• W2794351393 hasConceptScore W2794351393C2780091579 @default.
• W2794351393 hasConceptScore W2794351393C2780227381 @default.
• W2794351393 hasConceptScore W2794351393C2781068499 @default.
• W2794351393 hasConceptScore W2794351393C2908647359 @default.
• W2794351393 hasConceptScore W2794351393C44249647 @default.
• W2794351393 hasConceptScore W2794351393C71924100 @default.
• W2794351393 hasConceptScore W2794351393C82789193 @default.
• W2794351393 hasConceptScore W2794351393C95190672 @default.
• W2794351393 hasConceptScore W2794351393C99454951 @default.
• W2794351393 hasFunder F4320306078 @default.
• W2794351393 hasIssue "2" @default.
• W2794351393 hasLocation W27943513931 @default.
• W2794351393 hasLocation W27943513932 @default.
• W2794351393 hasLocation W27943513933 @default.
• W2794351393 hasLocation W27943513934 @default.
• W2794351393 hasOpenAccess W2794351393 @default.
• W2794351393 hasPrimaryLocation W27943513931 @default.
• W2794351393 hasRelatedWork W1900595920 @default.
• W2794351393 hasRelatedWork W2005931973 @default.

• next